Characterization of Oxaliplatin−DNA Adduct Formation in DNA and Differentiation of Cancer Cell Drug Sensitivity at Microdose Concentrations | doi.page

0 citations0 references

Characterization of Oxaliplatin−DNA Adduct Formation in DNA and Differentiation of Cancer Cell Drug Sensitivity at Microdose Concentrations

Chemical Research in Toxicology2007Vol. 20(12), pp. 1745–1751

Citations Over TimeTop 10% of 2007 papers

Sang Soo Hah, Rhoda A. Sumbad, Ralph W. de Vere White, Kenneth W. Turteltaub, Paul T. Henderson

Abstract

(trans-R, R)-1,2-diaminocyclohexaneoxalatoplatinum(II) (oxaliplatin) is a recently approved platinum analogue for use in the chemotherapy of metastatic colorectal cancer. Like many cytotoxic drugs, oxaliplatin exerts its antitumor effects by covalent modification of DNA. We report an accelerator mass spectrometry (AMS) assay to measure the kinetics of oxaliplatin-induced DNA damage and repair. We determined the apparent rate of oxaliplatin adduction to salmon sperm DNA. The oxaliplatin-DNA adduct distribution was further investigated at the nucleoside level by HPLC-AMS. Cultured platinum-sensitive testicular (833K) and platinum-resistant breast and bladder (MDA-MB-231 and T24, respectively) cancer cells were incubated with a subpharmacological concentration of oxaliplatin (0.2 microM). Both cellular and DNA radiocarbon contents in the drug-sensitive testicular cells had approximately twice the area under the curve as compared to the more platinum-resistant cell lines, implying that differential accumulation of the drug may be responsible for the sensitivity of cancer cells to platinum treatment. The lowest concentration of radiocarbon measured was approximately 1+/-0.1 amol/microg of DNA, when assaying 1 microg of DNA. This sensitivity for measuring oxaliplatin-DNA adducts is the highest reported to date. The sensitivity offered by this method may be applicable to other DNA-damaging drugs, metabolisms studies, and diagnostics development.

Related Papers

→ Approaches using molecular imaging technology — use of PET in clinical microdose studies(2010)110 cited
→ The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future(2024)6 cited
Pediatric Microdose Study of ( 14 C)Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept Miriam G. MooijEsther van DuijnCatherijne A. J. KnibbeAlbert D. Windhorst • N. Harry HendrikseWouter H. J. VaesEdwin SpaansBabs O. Fabriek • Hugo SandmanDimitri GrossouwLidwien M. HanffPaul J. J. M. Janssen • Birgit C. P. KochDick TibboelSaskia N. de Wildt(2014)
→ Study of Ultra‐Sensitive AMS Method to Identify Drug–Drug Interactions between Ciprofloxacin and Microdose 14C‐Caffeine(2018)